LEADER 04862nam  2200757Ia 450 
001 9910969384203321
005 20251017110116.0
010   $a9780309253185
010   $a0309253187
010   $a9781283636360
010   $a1283636360
010   $a9780309253161
010   $a0309253160
035   $a(CKB)2670000000275075
035   $a(EBL)3379028
035   $a(SSID)ssj0000665821
035   $a(PQKBManifestationID)11396035
035   $a(PQKBTitleCode)TC0000665821
035   $a(PQKBWorkID)10646588
035   $a(PQKB)10153786
035   $a(Au-PeEL)EBL3379028
035   $a(CaPaEBR)ebr10606369
035   $a(CaONFJC)MIL394882
035   $a(OCoLC)902942425
035   $a(MiAaPQ)EBC3379028
035   $a(Perlego)4739707
035   $a(DNLM)1601246
035   $a(BIP)62386489
035   $a(BIP)39416916
035   $a(EXLCZ)992670000000275075
100   $a20111220d2012      uy         0
101 0 $aeng
135   $aurcn|||||||||
181   $ctxt
182   $cc
183   $acr
200 00$aEnvisioning a transformed clinical trials enterprise in the United States $eestablishing an agenda for 2020: workshop summary /$fNeil Weisfeld, Rebecca A. English, and Anne B. Claiborne, rapporteurs; Forum on Drug Discovery, Development, and Translation; Board on Health Sciences Policy
205   $a1st ed.
210   $aWashington $cNational Academies Press$d2012
215   $a1 online resource (232 p.)
300   $aDescription based upon print version of record.
311 08$a9780309253154 
311 08$a0309253152 
320   $aIncludes bibliographical references.
327   $a""Front Matter""; ""Reviewers""; ""Contents""; ""Tables, Figures, and Boxes""; ""Acronyms""; ""1 Introduction""; ""2 Integrating Community Practice and Clinical Trials""; ""3 Improving Public Participation in Clinical Trials""; ""4 Creating a New Business Model for Clinical Trials""; ""5 Building an Infrastructure to Support Clinical Trials""; ""6 Suggesting an Agenda for Transforming Elements of the Clinical Trials Enterprise""; ""References""; ""Appendix A: Workshop Agenda""; ""Appendix B: Participant Biographies""; ""Appendix C: Registered Workshop Attendees""
327   $a""Appendix D: Discussion Paper: The Clinical Trials Enterprise in the United States: A Call for Disruptive Innovation""""Appendix E: Discussion Paper: Developing a Robust Clinical Trials Workforce""; ""Appendix F: Discussion Paper: Transforming the Economics of Clinical Trials""; ""Appendix G: Discussion Paper: Developing a Clinical Trials Infrastructure""; ""Appendix H: Discussion Paper: Canadian Strategy on Patient-Oriented Research""; ""Appendix I: Discussion Paper: Health Research as a Public Good""; ""Appendix J: Discussion Paper: Novel Ways to Get Good Trial Data: The UK Experience""
327   $a""Appendix K: IOM Staff Paper: Context and Glossary of Select Terms Associated with the Clinical Trials Enterprise""
330   $aThere is growing recognition that the United States' clinical trials enterprise (CTE) faces great challenges. There is a gap between what is desired - where medical care is provided solely based on high quality evidence - and the reality - where there is limited capacity to generate timely and practical evidence for drug development and to support medical treatment decisions. With the need for transforming the CTE in the U.S. becoming more pressing, the IOM Forum on Drug Discovery, Development, and Translation held a two-day workshop in November 2011, bringing together leaders in research and health care. The workshop focused on how to transform the CTE and discussed a vision to make the enterprise more efficient, effective, and fully integrated into the health care system. Key issue areas addressed at the workshop included: the development of a robust clinical trials workforce, the alignment of cultural and financial incentives for clinical trials, and the creation of a sustainable infrastructure to support a transformed CTE. This document summarizes the workshop.
606   $aClinical trials$zUnited States
606   $aClinical medicine$xResearch$zUnited States
615  0$aClinical trials
615  0$aClinical medicine$xResearch
676   $a615.50724
701   $aWeisfeld$b Neil E$01805912
701   $aEnglish$b Rebecca A$01805913
701   $aClaiborne$b Anne B$01805914
712 02$aInstitute of Medicine (U.S.).$bForum on Drug Discovery, Development, and Translation.
712 02$aInstitute of Medicine (U.S.).$bBoard on Health Sciences Policy.
712 02$aNational Academies Press (U.S.)
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910969384203321
996   $aEnvisioning a transformed clinical trials enterprise in the United States$94354792
997   $aUNINA